Bob Nelsen (Michael Kovac/Getty Images)
A year after debuting with $500M, Bob Nelsen's Really Big Neuroscience Company raises a really not-as-big Series B
In putting together another nine-figure financing round, ARCH-backed Neumora is attempting to straddle the very fine line between hype and surreptitiousness.
Last October, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
